CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer.
Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
通过转基因方式表达人嵌合抗原受体(CAR)的T淋巴细胞,已在部分血液系统癌症的基因和细胞免疫治疗中显示疗效和安全性。要使治疗性细胞产品具有足够生物效力且制造成本可行,需要适当的基因载体和基因工程方法。转座子介导的基因转移可满足这些需求,目前正在临床试验中评估。本方案介绍用于在人细胞中稳定整合基因的Sleeping Beauty(SB)转座子载体基本组分,尤其关注小环DNA载体和合成mRNA的使用。文中提供基于荧光报告基因表达、在培养的人细胞系中验证载体组分功能的方案,并介绍CAR-T 细胞工程化流程及检测多克隆细胞群中转基因表达、生物效力和基因组载体拷贝数的实验。由于转座子可使用裸核酸实现无病毒基因转移,任何具备生物安全一级设施的实验室均可采用该方案。
Human T lymphocytes that transgenically express a chimeric antigen receptor (CAR) have proven efficacy and safety in gene- and cell-based immunotherapy of certain hematological cancers. Appropriate gene vectors and methods of genetic engineering are required for therapeutic cell products to be biologically potent and their manufacturing to be economically viable.
Transposon-based gene transfer satisfies these needs, and is currently being evaluated in clinical trials. In this protocol we describe the basic Sleeping Beauty (SB) transposon vector components required for stable gene integration in human cells, with special emphasis on minicircle DNA vectors and the use of synthetic mRNA.
We provide a protocol for functional validation of the vector components in cultured human cell lines on the basis of fluorescent reporter gene expression.
Finally, we provide a protocol for CAR-T cell engineering and describe assays that address transgene expression, biological potency and genomic vector copy numbers in polyclonal cell populations. Because transposons allow virus-free gene transfer with naked nucleic acids, the protocol can be adopted by any laboratory equipped with biological safety level S1 facilities.
MEMBER ACCOUNT
登录成功会直接打开下一页。